Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

The Generalized Data Model for clinical research.

Danese MD, Halperin M, Duryea J, Duryea R.

BMC Med Inform Decis Mak. 2019 Jun 24;19(1):117. doi: 10.1186/s12911-019-0837-5.

2.

Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe.

Khunti K, Danese MD, Kutikova L, Catterick D, Sorio-Vilela F, Gleeson M, Kondapally Seshasai SR, Brownrigg J, Ray KK.

JAMA Netw Open. 2018 Dec 7;1(8):e185554. doi: 10.1001/jamanetworkopen.2018.5554.

3.

Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: an observational cohort study using SEER Medicare data.

Danese MD, Katz A, Cetin K, Chia V, Gleeson ML, Kelsh M, Griffiths RI.

Leuk Lymphoma. 2019 Aug;60(8):2015-2024. doi: 10.1080/10428194.2018.1555329. Epub 2019 Jan 11.

PMID:
30632830
4.

The prevalence, low-density lipoprotein cholesterol levels, and treatment of patients at very high risk of cardiovascular events in the United Kingdom: a cross-sectional study.

Danese MD, Sidelnikov E, Kutikova L.

Curr Med Res Opin. 2018 Aug;34(8):1441-1447. doi: 10.1080/03007995.2018.1463211. Epub 2018 Apr 20.

PMID:
29627994
5.

Methods for estimating costs in patients with hyperlipidemia experiencing their first cardiovascular event in the United Kingdom.

Danese MD, Gleeson M, Griffiths RI, Catterick D, Kutikova L.

J Med Econ. 2017 Sep;20(9):931-937. doi: 10.1080/13696998.2017.1345747. Epub 2017 Jul 4.

PMID:
28635339
6.

Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study.

Danese MD, Gleeson M, Kutikova L, Griffiths RI, Khunti K, Seshasai SRK, Ray KK.

BMJ Open. 2017 May 10;7(5):e013851. doi: 10.1136/bmjopen-2016-013851.

7.

Facility-level CKD-MBD composite score and risk of adverse clinical outcomes among patients on hemodialysis.

Block GA, Yusuf AA, Danese MD, Wirtz HS, Hu Y, Do TP, Cooper K, Gilbertson DT, Bradbury BD, Collins AJ.

BMC Nephrol. 2016 Nov 4;17(1):166.

8.

Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy.

Danese MD, Griffiths RI, Gleeson ML, Dalvi T, Li J, Mikhael JR, Deeter R, Dreyling M.

Leuk Lymphoma. 2017 May;58(5):1094-1104. doi: 10.1080/10428194.2016.1228924. Epub 2016 Sep 23. Erratum in: Leuk Lymphoma. 2017 May;58(5):1275.

PMID:
27659997
9.

Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK.

Danese MD, Gleeson M, Kutikova L, Griffiths RI, Azough A, Khunti K, Seshasai SR, Ray KK.

BMJ Open. 2016 Aug 5;6(8):e011805. doi: 10.1136/bmjopen-2016-011805.

10.

Racial and Ethnic Variability in the Prevalence and Incidence of Comorbidities Associated with Gastric Cancer in the United States.

Lowe KA, Danese MD, Gleeson ML, Langeberg WJ, Ke J, Kelsh MA.

J Gastrointest Cancer. 2016 Jun;47(2):168-81. doi: 10.1007/s12029-016-9809-5.

PMID:
26961791
11.

Quality adjusted life year gains associated with administration of recombinant tissue-type plasminogen activator for treatment of acute ischemic stroke: 1998-2011.

Lubeck DP, Danese MD, Duryea J, Halperin M, Tayama D, Yu E, Lalla D, Grotta JC.

Int J Stroke. 2016 Feb;11(2):198-205. doi: 10.1177/1747493015609776.

PMID:
26783311
12.

Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data.

Danese MD, Reyes CM, Gleeson ML, Halperin M, Skettino SL, Mikhael J.

Med Care. 2016 Apr;54(4):343-9. doi: 10.1097/MLR.0000000000000486.

13.

Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.

Danese MD, Masaquel A, Santos E, Brammer M, Lee A, Lalla D.

Value Health. 2015 Sep;18(6):876-83. doi: 10.1016/j.jval.2015.06.003. Epub 2015 Aug 13.

14.

Refining the definition of clinically important mineral and bone disorder in hemodialysis patients.

Danese MD, Halperin M, Lowe KA, Bradbury BD, Do TP, Block GA.

Nephrol Dial Transplant. 2015 Aug;30(8):1336-44. doi: 10.1093/ndt/gfv034. Epub 2015 Mar 27.

15.

Undiagnosed diabetes in breast, colorectal, lung, and prostate cancer: incidence and risk factors.

Griffiths RI, Lindquist KJ, O'Malley CD, Gleeson ML, Duryea JL, Valderas JM, Danese MD.

ISRN Oncol. 2014 Mar 4;2014:607850. doi: 10.1155/2014/607850. eCollection 2014.

16.

Impact of undetected comorbidity on treatment and outcomes of breast cancer.

Griffiths RI, Gleeson ML, Valderas JM, Danese MD.

Int J Breast Cancer. 2014;2014:970780. doi: 10.1155/2014/970780. Epub 2014 Feb 13.

17.

CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis.

Block GA, Kilpatrick RD, Lowe KA, Wang W, Danese MD.

Clin J Am Soc Nephrol. 2013 Dec;8(12):2132-40. doi: 10.2215/CJN.04260413. Epub 2013 Sep 19.

18.

Misclassification of incident conditions using claims data: impact of varying the period used to exclude pre-existing disease.

Griffiths RI, O'Malley CD, Herbert RJ, Danese MD.

BMC Med Res Methodol. 2013 Mar 6;13:32. doi: 10.1186/1471-2288-13-32.

19.

Prevalence and incidence of comorbidities in elderly women with ovarian cancer.

Chia VM, O'Malley CD, Danese MD, Lindquist KJ, Gleeson ML, Kelsh MA, Griffiths RI.

Gynecol Oncol. 2013 May;129(2):346-52. doi: 10.1016/j.ygyno.2013.02.014. Epub 2013 Feb 17.

PMID:
23422502
20.

Epidemiology and outcomes of previously undiagnosed diabetes in older women with breast cancer: an observational cohort study based on SEER-Medicare.

Griffiths RI, Danese MD, Gleeson ML, Valderas JM.

BMC Cancer. 2012 Dec 22;12:613. doi: 10.1186/1471-2407-12-613.

21.
22.

Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare.

Griffiths RI, Gleeson ML, Danese MD, O'Hagan A.

Value Health. 2012 Jul-Aug;15(5):656-63. doi: 10.1016/j.jval.2012.03.1388. Epub 2012 Jun 22.

23.

Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.

Griffiths RI, Gleeson ML, Mikhael J, Dreyling MH, Danese MD.

Cancer. 2012 Dec 15;118(24):6079-88. doi: 10.1002/cncr.27638. Epub 2012 May 30.

24.

Effect of central nervous system metastases on treatment discontinuation and survival in older women receiving trastuzumab for metastatic breast cancer.

Danese MD, Lindquist K, Doan J, Lalla D, Brammer M, Griffiths RI.

J Cancer Epidemiol. 2012;2012:819210. doi: 10.1155/2012/819210. Epub 2012 Apr 9.

25.

Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care.

Stasi R, Murali M, Michel M, Viallard JF, Giagounidis A, Janssens A, Legg J, Deuson R, Danese MD.

Int J Hematol. 2012 Jul;96(1):26-33. doi: 10.1007/s12185-012-1088-8. Epub 2012 May 5.

PMID:
22562409
26.

Impact of hemodialysis catheter dysfunction on dialysis and other medical services: an observational cohort study.

Griffiths RI, Newsome BB, Leung G, Block GA, Herbert RJ, Danese MD.

Int J Nephrol. 2012;2012:673954. doi: 10.1155/2012/673954. Epub 2012 Feb 12.

27.

Patterns of Hemodialysis Catheter Dysfunction Defined According to National Kidney Foundation Guidelines As Blood Flow <300 mL/min.

Griffiths RI, Newsome BB, Block GA, Herbert RJ, Danese MD.

Int J Nephrol. 2011;2011:891259. doi: 10.4061/2011/891259. Epub 2011 Dec 8.

28.

An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer.

Danese MD, O'Malley C, Lindquist K, Gleeson M, Griffiths RI.

Ann Oncol. 2012 Jul;23(7):1756-65. doi: 10.1093/annonc/mdr486. Epub 2011 Oct 29.

29.

Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.

Griffiths RI, Barron RL, Gleeson ML, Danese MD, O'Hagan A, Chia VM, Legg JC, Lyman GH.

Pharmacoeconomics. 2012 Feb 1;30(2):103-18. doi: 10.2165/11589440-000000000-00000.

PMID:
21967155
30.

Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab.

Griffiths RI, Lalla D, Herbert RJ, Doan JF, Brammer MG, Danese MD.

Cancer Invest. 2011 Nov;29(9):573-84. doi: 10.3109/07357907.2011.616251. Epub 2011 Sep 19.

31.

The association of vitamin D use with hypercalcemia and hyperphosphatemia in hemodialysis patients: a case-crossover study.

Kilpatrick RD, Danese MD, Belozeroff V, Smirnakis K, Goodman WG, Rothman KJ.

Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):914-21. doi: 10.1002/pds.2183. Epub 2011 Jul 7.

PMID:
21735509
32.

Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration.

Bressler NM, Doan QV, Varma R, Lee PP, Suñer IJ, Dolan C, Danese MD, Yu E, Tran I, Colman S.

Arch Ophthalmol. 2011 Jun;129(6):709-17. doi: 10.1001/archophthalmol.2011.140.

PMID:
21670337
33.

An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia.

Danese MD, Griffiths RI, Gleeson M, Satram-Hoang S, Knopf K, Mikhael J, Reyes C.

Blood. 2011 Mar 31;117(13):3505-13. doi: 10.1182/blood-2010-08-301929. Epub 2010 Dec 29.

34.

Health care utilization and mortality among elderly patients with myelodysplastic syndromes.

Lindquist KJ, Danese MD, Mikhael J, Knopf KB, Griffiths RI.

Ann Oncol. 2011 May;22(5):1181-8. doi: 10.1093/annonc/mdq552. Epub 2010 Nov 1.

35.

Estimating recurrences prevented from using trastuzumab in HER-2/neu-positive adjuvant breast cancer in the United States.

Danese MD, Lalla D, Brammer M, Doan Q, Knopf K.

Cancer. 2010 Dec 15;116(24):5575-83. doi: 10.1002/cncr.25347. Epub 2010 Aug 23.

36.

Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura.

Danese MD, Lindquist K, Gleeson M, Deuson R, Mikhael J.

Am J Hematol. 2009 Oct;84(10):631-5. doi: 10.1002/ajh.21500.

37.

Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates.

Danese MD, Badamgarav E, Bauer DC.

J Bone Miner Res. 2009 Nov;24(11):1819-26. doi: 10.1359/jbmr.090506.

38.

Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL.

Bradbury BD, Danese MD, Gleeson M, Critchlow CW.

Clin J Am Soc Nephrol. 2009 Mar;4(3):630-7. doi: 10.2215/CJN.03580708. Epub 2009 Mar 4.

39.

Consistent control of mineral and bone disorder in incident hemodialysis patients.

Danese MD, Belozeroff V, Smirnakis K, Rothman KJ.

Clin J Am Soc Nephrol. 2008 Sep;3(5):1423-9. doi: 10.2215/CJN.01060308. Epub 2008 Jul 2.

40.
41.

Abnormal bone and mineral metabolism in kidney transplant patients--a review.

Sprague SM, Belozeroff V, Danese MD, Martin LP, Olgaard K.

Am J Nephrol. 2008;28(2):246-53. Epub 2007 Nov 7. Review.

42.

Catheter use is high even among hemodialysis patients with a fistula or graft.

Danese MD, Liu Z, Griffiths RI, Dylan M, Yu HT, Dubois R, Nissenson AR.

Kidney Int. 2006 Oct;70(8):1482-5. Epub 2006 Aug 30.

43.

Thyroid status, cardiovascular risk, and mortality in older adults.

Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy RP, Ladenson PW.

JAMA. 2006 Mar 1;295(9):1033-41.

44.

Mortality differences among organisms causing septicemia in hemodialysis patients.

Danese MD, Griffiths RI, Dylan M, Yu HT, Dubois R, Nissenson AR.

Hemodial Int. 2006 Jan;10(1):56-62.

PMID:
16441828
45.

PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis.

Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM.

Am J Kidney Dis. 2006 Jan;47(1):149-56.

PMID:
16377396
46.

Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis.

Nissenson AR, Dylan ML, Griffiths RI, Yu HT, Dean BB, Danese MD, Dubois RW.

Am J Kidney Dis. 2005 Aug;46(2):301-8.

PMID:
16112049
47.

Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature.

Danese MD, Ladenson PW, Meinert CL, Powe NR.

J Clin Endocrinol Metab. 2000 Sep;85(9):2993-3001. Review.

PMID:
10999775
48.

Evaluation of common problems in primary care: effects of physician, practice, and financial characteristics.

Meyer CM, Ladenson PW, Scharfstein JA, Danese MD, Powe NR.

Am J Manag Care. 2000 Apr;6(4):457-69.

49.

When to treat mild hypothyroidism.

Ayala AR, Danese MD, Ladenson PW.

Endocrinol Metab Clin North Am. 2000 Jun;29(2):399-415. Review.

PMID:
10874537
50.

Decision analysis in endocrinology and metabolism.

Powe NR, Danese MD, Ladenson PW.

Endocrinol Metab Clin North Am. 1997 Mar;26(1):89-111. Review.

PMID:
9074854

Supplemental Content

Loading ...
Support Center